ASH 2022 Conference Coverage

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

ASH 2022 Conference Coverage

Lymphoma
Leukemia
Myeloma
MDS and MPN
Benign Hematology

Playback speed

10 seconds

Selected Updates in MDS

By ASH 2022 Conference Coverage FEATURING Amer Zeidan

486 views

February 14, 2023

Comments 0

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

MDS and MPN

Ropeginterferon Alfa-2b vs. Standard Therapy for Low-Risk Pts With P…

ASH 2022 Conference Coverage

T. Barbui

182 views

MEDALIST Study: Multiple Episodes of Transfusion Independence With L…

ASH 2022 Conference Coverage

U. Platzbecker

191 views

Selected Updates in MDS

ASH 2022 Conference Coverage

A. Zeidan

486 views

Phase 2 FIGHT-203 Study: Pemigatinib in Pts With Myeloid/Lymphoid Ne…

ASH 2022 Conference Coverage

A. Vannucchi

436 views

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

ASH 2022 Conference Coverage

M. McMullin

1.2K views

ASH 2022: Venetoclax Combined With Cladribine, Idarubicin, Cytarabin…

ASH 2022 Conference Coverage

G. Borthakur

177 views

ASH 2022 Real-World Validation of Molecular International Prognostic…

ASH 2022 Conference Coverage

M. Della Porta

49 views

ASH 2022: Management of Accelerated and Blast-Phase MPN

ASH 2022 Conference Coverage

R. Rampal

57 views

ASH 2022: Navitoclax and Ruxolitinib in JAKi-Naïve Patients With MF …

ASH 2022 Conference Coverage

F. Passamonti

77 views

ASH 2022: What Is Complete HLA Match in 2022?

ASH 2022 Conference Coverage

S. Spellman

193 views

ASH 2022 Outcomes of Patients With Accelerated/Blast-Phase MPNs in t…

ASH 2022 Conference Coverage

A. Patel

107 views

ASH 2022 Phase II Study of Myeloablative 8/8- or 7/8-Matched AlloSCT…

ASH 2022 Conference Coverage

A. Hoover

28 views

Synergistic Activity of Luspatercept and Erythroid Stimulating Agent…

ASH 2022 Conference Coverage

R. Komrokji

282 views

Luspatercept for Treatment of LR-MDS: Real World Data Replicates MED…

ASH 2022 Conference Coverage

R. Komrokji

334 views

ASH 2022 Phase 1 Results of the First-in-Class CXCR1/2 Inhibitor SX-…

ASH 2022 Conference Coverage

D. Sallman

40 views

ASH 2022 Primary Results of STIMULUS-MDS1: A Randomized, Double-Blin…

ASH 2022 Conference Coverage

A. Zeidan

131 views

Phase 3b, Single-Arm, Multicenter Study to Assess the Efficacy, Safe…

ASH 2022 Conference Coverage

J. Mascarenhas

134 views

Validation of 2022 WHO & ICC Classifications in MDS - An Analysis on…

ASH 2022 Conference Coverage

S. Ball

192 views

ASH 2022 Results From Phase III BMT CTN 1703: Post-Transplant Cyclop…

ASH 2022 Conference Coverage

S. Holtan

352 views

ASH 2022 Efficacy & Safety of Add-On Parsaclisib to Ruxolitinib Ther…

ASH 2022 Conference Coverage

A. Yacoub

57 views

ASH 2022 Impact of Allelic State on Overall Survival in TP53-Mutant …

ASH 2022 Conference Coverage

J. Bewersdorf

92 views

Updated Results From the Momentum Phase 3 Study of Momelotinib vs. D…

ASH 2022 Conference Coverage

A. Gerds

233 views